Repligen Corporation reported its financial results for the second quarter of 2026, revealing total revenue of $204.1 million, a 11.9% increase from $182.4 million in the same period last year. For the first half of 2026, revenue reached $398.4 million, up 13.3% from $351.5 million in the first half of 2025. The growth was primarily driven by a 11.9% increase in product revenue, which amounted to $204.1 million for the quarter and $398.3 million for the six months. The company’s net income for the second quarter was $5.0 million, a decrease from $14.9 million in the prior year, while net income for the first half was $13.3 million, down from $20.7 million.

The company experienced a rise in operating expenses, which totaled $190.2 million for the second quarter, up 12.9% from $168.5 million a year earlier. This increase was attributed to higher costs in selling, general, and administrative expenses, which rose by 8.1% to $76.6 million, and research and development expenses, which increased by 3.2% to $14.4 million. Additionally, Repligen reported a loss of $13.7 million from the sale of Polymem S.A.S., which was completed in March 2026, contributing to the decline in net income.

In terms of operational metrics, Repligen's cash and cash equivalents increased to $606.8 million as of June 30, 2026, compared to $566.0 million at the end of 2025. The company also reported a total of $203.7 million in marketable securities, reflecting a slight increase from $201.6 million at the end of the previous year. The company’s total assets remained stable at $2.95 billion, with total liabilities decreasing to $838.1 million from $843.6 million at the end of 2025. The company’s employee headcount has also increased, reflecting its ongoing investment in growth and expansion.

Looking ahead, Repligen has announced plans to acquire BioLife Solutions, Inc. for approximately $1.5 billion, which is expected to close in the fourth quarter of 2026. This acquisition aims to enhance Repligen's portfolio in the cell and gene therapy market. The company continues to focus on expanding its bioprocessing business and investing in research and development to drive future growth. Despite the challenges posed by inflation and supply chain disruptions, Repligen remains optimistic about its strategic initiatives and market opportunities.

About REPLIGEN CORP

Repligen is a global life sciences company specializing in innovative bioprocessing technologies and systems that enhance the efficiency, scalability, and flexibility of biologic drug manufacturing. Its core offerings include filtration, chromatography, process analytics, and proteins, serving biopharmaceutical, gene therapy, and vaccine markets. The company focuses on integrated solutions, continuous innovation, and strategic acquisitions to support biologics, mRNA, and gene therapy production worldwide.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov